Asset profile
baricitinib · Olumiant
Small molecule
Evidence outlook
Approved: Rheumatoid Arthritis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Atopic Dermatitis · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
123 competitors in this universe: 7 direct rivals (same mechanism and indication), 0 same-class, 116 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Baricitinib (Olumiant): this drug | Approved | Small molecule | JAK, JAK1/2 | ||
| Ruxolitinib | Approved | Small molecule | JAK1/2 | ||
| Tofacitinib (Xeljanz) | Approved | Small molecule | JAK, JAK1/JAK3 | ||
| Upadacitinib (Rinvoq) | Approved | Small molecule | JAK, JAK1 | ||
| Filgotinib (Jyseleca) | Phase 3 | Small molecule | JAK, JAK1 | ||
| Pumecitinib | Phase 3 | Small molecule | JAK1/2 | ||
| QLM3003 | Phase 3 | Small molecule | JAK | ||
| ZL-82 | Phase 2 | Small molecule | JAK | ||
| Abatacept (Orencia) | Approved | Protein / enzyme therapeutic | CD80/CD86 (CTLA-4-Ig), Selective T Cell Costimulation Modulator, CD80/CD86 (B7-1/B7-2) on antigen-presenting cells | ||
| Abrocitinib (Cibinqo) | Approved | Small molecule | JAK1 | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Ryvk (Simlandi) | Approved | — | TNF-alpha | ||
| Aldesleukin (Proleukin) | Approved | Recombinant Cytokine (il-2) | Interleukin-2 receptor (IL-2R) | ||
| Anakinra (r-metHuIL-1ra) | Approved | Protein / enzyme therapeutic | Interleukin-1 receptor (IL-1R), Interleukin-1 receptor type 1 (IL-1R1) | ||
| Certolizumab Pegol (Cimzia) | Approved | Antibody fragment | TNF-alpha |
…and 108 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
1 further head-to-head pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(34 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (3)
October 2026 (1)
What to watch
November 2026 (1)
What to watch
December 2026 (1)
What to watch
2027 (9)
March 2027 (2)
June 2027 (1)
What to watch
July 2027 (1)
What to watch
August 2027 (1)
What to watch
October 2027 (1)
What to watch
November 2027 (1)
What to watch
December 2027 (2)
2028 (11)
January 2028 (2)
February 2028 (1)
What to watch
March 2028 (2)
July 2028 (2)
August 2028 (1)
September 2028 (2)
November 2028 (1)
What to watch
2029 (5)
April 2029 (1)
What to watch
May 2029 (1)
What to watch
September 2029 (1)
What to watch
November 2029 (1)
What to watch
December 2029 (1)
What to watch
2030 (4)
February 2030 (1)
What to watch
May 2030 (1)
What to watch
July 2030 (1)
What to watch
December 2030 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.